Marco Cavaleri

10.0k total citations
38 papers, 823 citations indexed

About

Marco Cavaleri is a scholar working on Infectious Diseases, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Marco Cavaleri has authored 38 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 7 papers in Epidemiology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Marco Cavaleri's work include SARS-CoV-2 and COVID-19 Research (7 papers), Vaccine Coverage and Hesitancy (6 papers) and Antimicrobial Resistance in Staphylococcus (5 papers). Marco Cavaleri is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (7 papers), Vaccine Coverage and Hesitancy (6 papers) and Antimicrobial Resistance in Staphylococcus (5 papers). Marco Cavaleri collaborates with scholars based in Netherlands, United States and United Kingdom. Marco Cavaleri's co-authors include Eric Pelfrene, Harald Enzmann, Emer Cooke, Sabine M. J. M. Straus, Marco Mura, Efthymios Manolis, Joachim Hombach, Daniela Jabés, Annelies Wilder‐Smith and Gianpaolo Candiani and has published in prestigious journals such as The Lancet, Nature Communications and Clinical Infectious Diseases.

In The Last Decade

Marco Cavaleri

33 papers receiving 786 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marco Cavaleri Netherlands 16 421 183 164 142 95 38 823
В. Г. Акимкин Russia 16 305 0.7× 81 0.4× 214 1.3× 219 1.5× 78 0.8× 197 885
Oren Zimhony Israel 20 965 2.3× 105 0.6× 507 3.1× 364 2.6× 69 0.7× 62 1.7k
Daniel B. Chastain United States 18 474 1.1× 148 0.8× 493 3.0× 136 1.0× 27 0.3× 109 1.1k
Jae–Hoon Song South Korea 16 278 0.7× 200 1.1× 300 1.8× 75 0.5× 16 0.2× 36 786
Paul Crook United Kingdom 18 379 0.9× 97 0.5× 254 1.5× 92 0.6× 60 0.6× 46 1.1k
Jan Egil Afset Norway 19 580 1.4× 195 1.1× 265 1.6× 179 1.3× 64 0.7× 67 1.2k
Lina Zhong United States 16 272 0.6× 91 0.5× 248 1.5× 255 1.8× 29 0.3× 42 859
Christopher Finn McQuaid United Kingdom 14 594 1.4× 59 0.3× 307 1.9× 79 0.6× 36 0.4× 48 1.1k
Ioana D. Olaru Germany 16 549 1.3× 74 0.4× 444 2.7× 135 1.0× 23 0.2× 80 1.2k
Atef M. Shibl Saudi Arabia 14 363 0.9× 91 0.5× 174 1.1× 120 0.8× 14 0.1× 33 640

Countries citing papers authored by Marco Cavaleri

Since Specialization
Citations

This map shows the geographic impact of Marco Cavaleri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Cavaleri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Cavaleri more than expected).

Fields of papers citing papers by Marco Cavaleri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Cavaleri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Cavaleri. The network helps show where Marco Cavaleri may publish in the future.

Co-authorship network of co-authors of Marco Cavaleri

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Cavaleri. A scholar is included among the top collaborators of Marco Cavaleri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Cavaleri. Marco Cavaleri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaminski, Robert W., Patricia B. Pavlinac, Elizabeth T. Rogawski McQuade, et al.. (2025). WHO Workshop Report: Regulatory Science to Inform Clinical Pathways for Shigella Vaccines Intended for Use in Children in Low- and Middle-Income Countries. Vaccines. 13(5). 439–439.
2.
Cavaleri, Marco, Adam Hacker, Murray Lumpkin, et al.. (2025). A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems. The Lancet Global Health. 13(4). e769–e777. 6 indexed citations
3.
Doaré, Kirsty Le, Marco Cavaleri, Godwin Enwere, et al.. (2025). Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries. Vaccine. 58. 127131–127131. 3 indexed citations
4.
Moon, Kyung D., Carmen Coxon, Christine Årdal, et al.. (2025). Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance. Nature Communications. 16(1). 10883–10883.
5.
Excler, Jean‐Louis, Tarun Saluja, Annelies Wilder‐Smith, et al.. (2025). Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations. Vaccine. 62. 127515–127515.
6.
Cavaleri, Marco, et al.. (2025). T cells responses after vaccination: a regulatory perspective. Frontiers in Immunology. 16. 1584738–1584738.
7.
Andeweg, Arno C., et al.. (2024). Myocarditis associated with COVID-19 vaccination. npj Vaccines. 9(1). 122–122. 19 indexed citations
8.
Asturias, Edwin J., Jean‐Louis Excler, James Ackland, et al.. (2023). Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring. Clinical Infectious Diseases. 77(6). 917–924. 8 indexed citations
9.
Cavaleri, Marco, et al.. (2021). Shaping EU medicines regulation in the post COVID-19 era. The Lancet Regional Health - Europe. 9. 100192–100192. 15 indexed citations
10.
Pelfrene, Eric, et al.. (2021). Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight?. Antimicrobial Resistance and Infection Control. 10(1). 21–21. 62 indexed citations
11.
Monnier, Annelie A, Evelina Tacconelli, Christine Årdal, Marco Cavaleri, & Inge C. Gyssens. (2020). A case study on Staphylococcus aureus bacteraemia: available treatment options, antibiotic R&D and responsible antibiotic-use strategies. JAC-Antimicrobial Resistance. 2(2). dlaa034–dlaa034. 2 indexed citations
12.
Lienhardt, Christian, et al.. (2019). Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance. PLoS Medicine. 16(9). e1002915–e1002915. 11 indexed citations
13.
Pelfrene, Eric, et al.. (2019). The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis. PLoS neglected tropical diseases. 13(6). e0007381–e0007381. 32 indexed citations
14.
Baay, Marc, Thomas L. Richie, Pieter Neels, et al.. (2018). Human challenge trials in vaccine development, Rockville, MD, USA, September 28–30, 2017. Biologicals. 61. 85–94. 18 indexed citations
15.
Pelfrene, Eric, et al.. (2016). Bacteriophage therapy: a regulatory perspective. Journal of Antimicrobial Chemotherapy. 71(8). 2071–2074. 98 indexed citations
16.
17.
Pfleiderer, Michael, Jean‐Hugues Trouvin, Daniel Brasseur, et al.. (2014). Summary of knowledge gaps related to quality and efficacy of current influenza vaccines. Vaccine. 32(35). 4586–4591. 10 indexed citations
18.
Li, Xuguang, Carolyn A. Wilson, Robert Ball, et al.. (2013). A global regulatory science agenda for vaccines. Vaccine. 31. B163–B175. 30 indexed citations
19.
Cavaleri, Marco, et al.. (2005). Pharmacokinetics and excretion of dalbavancin in the rat. Journal of Antimicrobial Chemotherapy. 55(suppl_2). ii31–ii35. 50 indexed citations
20.
Dowell, James A., Alice B. Gottlieb, Anton Leighton, et al.. (2002). The pharmacokinetics and renal excretion of dalbavancin in healthy subjects. 42. 18. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by В. Г. Акимкин Breakdown of academic impact, for papers by Oren Zimhony Breakdown of academic impact, for papers by Daniel B. Chastain Breakdown of academic impact, for papers by Jae–Hoon Song Breakdown of academic impact, for papers by Paul Crook Breakdown of academic impact, for papers by Jan Egil Afset Breakdown of academic impact, for papers by Lina Zhong Breakdown of academic impact, for papers by Christopher Finn McQuaid Breakdown of academic impact, for papers by Ioana D. Olaru Breakdown of academic impact, for papers by Atef M. Shibl
Rankless by CCL
2026